WO2002087660A1 - Procedes et dispositif de filtration du sang - Google Patents
Procedes et dispositif de filtration du sang Download PDFInfo
- Publication number
- WO2002087660A1 WO2002087660A1 PCT/JP2002/004201 JP0204201W WO02087660A1 WO 2002087660 A1 WO2002087660 A1 WO 2002087660A1 JP 0204201 W JP0204201 W JP 0204201W WO 02087660 A1 WO02087660 A1 WO 02087660A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- filter
- filtration
- concentration gradient
- cell concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0218—Multiple bag systems for separating or storing blood components with filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0218—Multiple bag systems for separating or storing blood components with filters
- A61M1/0222—Multiple bag systems for separating or storing blood components with filters and filter bypass
Definitions
- the present invention relates to a blood filtration method and a blood filtration device for removing leukocytes from blood using a leukocyte removal filter.
- component transfusion in which the recipient only transfuses the necessary components
- component blood transfusion has become the mainstream of transfusion medicine today.
- advantages such as the ability to reduce the burden on blood recipients and increase the therapeutic effect.
- Blood component products such as concentrated red blood cell products, concentrated platelet products, and plasma products used for component transfusion are adjusted by centrifuging whole blood products obtained by donating blood.
- a large amount of leukocytes is mixed in the blood component preparation prepared in this way, and the mixed leukocytes cause relatively minor side effects such as headache, nausea, chills, and non-hemolytic fever reaction accompanying blood transfusion.
- a leukocyte removal filter filled with a filter medium such as a body has been widely used.
- Leukocyte removal using a leukocyte removal filter can be broadly divided into removal from whole blood products and removal after adjusting each blood component product.
- the latter requires a filter for each blood component product, while the former removes leukocytes from whole blood products with a single filter and then centrifugs to remove multiple types of leukocytes. It is considered to be a more preferable method because the blood component preparation can be adjusted.
- the so-called closed system in which a bag for whole blood products, a filter, and a bag for each blood component product that is adjusted after centrifugation are integrated, enabling the aseptic removal of leukocyte-free blood component products, has attracted attention. It has been used in blood centers and the like (Japanese Patent Application Laid-Open No. 1-302464).
- a method of adjusting blood from which leukocytes have been removed using a filter at a blood center, etc. includes a bag containing a large amount of white blood cells, a filter, and a bag for collecting blood filtered by the filter. This is performed using a system connected through a flexible tube such as chloride chloride.
- a bag containing blood from which leukocytes have not been removed is hung over a rack having hooks and the like, suspended at a head of about 0.5 to 2 m, and the blood from which leukocytes have not been removed is mixed well to obtain a homogeneous state.
- the clamp and breakable seal in the tube are manually released, and the blood from which leukocytes have been removed through a filter is collected in a collection bag. This operation is performed substantially continuously in order to minimize the restriction on the filter operator.
- whole blood products are generally filtered in the fresh state within 3 days, at most within several hours after blood collection. It is known that filtering fresh and hot whole blood products, particularly less than 1 hour after blood collection, reduces the filter's ability to remove leukocytes.
- Japanese Patent No. 2521090 discloses that a filter material is made of water or an aqueous solution of a water-soluble substance that is less harmful to living organisms and is in a wet state with a saturated water content or higher. Discloses a filter held by the company. This is a technique for improving platelet recovery by suppressing platelet stickiness by pre-wetting the filter material with an aqueous solution such as physiological saline, but the present inventors have studied that high leukocytes It was not possible to obtain a sufficient platelet recovery rate improvement effect while maintaining the removal performance. Further, since the filter disclosed herein is pre-wetted with a physiological saline solution or the like, if air is accidentally introduced into the filter, it is difficult to exhaust the air out of the filter device. However, blood flow may be reduced or stopped.
- a method is also known in which a whole blood product is centrifuged to fractionate into blood component products, and then filtered with a filter.
- a whole blood product is subjected to a very strong centrifugation at 3,520 X g to produce plasma, a buffy coat containing a large amount of platelets, and a concentrated red blood cell.
- a method of separating into three components of which the buffy coat and the concentrated red blood cells are sequentially filtered with one filter.
- WO92 / 077566 discloses that whole blood obtained by blood collection is separated into a concentrated erythrocyte preparation and platelet-rich plasma by light centrifugation, and each component is filtered through a separate filter. A method and system is disclosed. According to this method, all blood components to be finally adjusted are leukocyte-depleted, but require a complicated operation of inserting two filters into a centrifugal cup together with multiple bags. . In addition, there was a problem that the cost was high because two filters were required.
- filters that selectively remove leukocytes from platelet preparations such as platelet concentrates and platelet-rich plasma prepared by whole blood products or component blood sampling devices are commercially available, and are used in blood centers and clinical settings. If such a filter is used, high adhesiveness and platelets can be recovered to some extent, but platelet recovery varies due to individual differences in blood and other factors, and there is room for further improvement in the stability of the platelet recovery rate. Remains.
- Japanese Patent Application Laid-Open No. H10-212322 A discloses an apparatus for automatically filtering blood while maintaining a constant flow rate using a pump.
- Such a device is a device that controls the operation of the pump in response to pressure fluctuations by a controller while monitoring the pressure near the filter-inlet, and maintains an appropriate blood filtration flow rate.
- Japanese Patent Application Laid-Open No. Hei 9-1098334 discloses a timer, a sensor for optically detecting a liquid surface or a gas-liquid interface, and a method for detecting the weight of blood, when a predetermined amount of blood has been processed.
- a device which automatically detects the weight by detecting a weight sensor, a pressure sensor for detecting the pressure of a tube, or the like, and automatically stops the filtration.
- it is not only necessary to automate the blood filtration process, but also to record the filtration data (filtration time, temperature, flow rate, etc.) of individual blood on a computer.
- a possible automatic filtration device has been developed (Vox Sanguinis Vo 1.78 (Supplement 1), 2000, P5 17, P5 18).
- This device can automate the simultaneous simultaneous filtration of as many as 40 blood by a filter while mechanically automatically mixing blood not only before filtration but also during filtration, and automatically record filtration data.
- the above-mentioned apparatus is an automatic filtration apparatus for automatically performing the automatic filtration of blood in a homogeneous state, the automatic filtration for securing a constant flow rate, and the stop of the filtration.
- the blood filtration device of the present invention is an automatic filtration starter suitable for performing a blood filtration method for improving the performance of the filter of the present invention, and is different from the automatic filtration device described here. It is.
- Figure 1 is a schematic diagram showing an embodiment of the blood filtration device of the present invention
- FIG. 2 is a schematic diagram showing another embodiment of the blood filtration device of the present invention
- FIG. 3 is a block diagram showing a control system of the blood filtration device shown in FIGS. 1 and 2
- 2 is a partial side view showing an embodiment of a sensor and a blood storage unit when an optical sensor is used as a signal generating unit;
- FIG. 5 is a partial side view showing another embodiment of the sensor and the blood reservoir when an optical sensor is used as a signal generating means;
- FIG. 6 is a partial side view showing still another embodiment of the sensor and the blood storage section when an optical sensor is used as a signal generating means.
- a first object of the present invention is to provide a blood filtration method which improves the filtration performance of a filter and is easy to operate. More specifically, without increasing the filter capacity
- blood filtration methods that can remove leukocytes from highly fresh whole blood products with high efficiency, or platelet preparations derived from whole blood products or whole blood products or component blood samples, while maintaining high leukocyte removal ability while maintaining high platelets
- An object of the present invention is to provide a blood filtration method capable of stably achieving a recovery rate.
- the first object of the present invention is to provide a method of filtering out a heterogeneous blood having a blood cell concentration gradient in a storage section for storing blood represented by a blood bag. Can be achieved.
- a second object of the present invention is to provide an automatic filtration starter suitable for the blood filtration method of the present invention.
- the present inventors provided signal generating means for generating a signal after an appropriate blood cell concentration gradient was formed, and operating means for automatically canceling the flow control means based on a signal from the signal generating means. It has been found that the above second object can be achieved by using a blood filtration device.
- the object of the present invention is achieved by the following blood filtration method and blood filtration device.
- a blood filtration method for removing leukocytes from blood in which a blood cell concentration gradient is formed in a reservoir that stores blood, the blood is filtered through a leukocyte removal filter, and the filtered blood is collected in a collection unit.
- Blood filtration method for removing leukocytes from blood, in which a blood cell concentration gradient is formed in a reservoir that stores blood, the blood is filtered through a leukocyte removal filter, and the filtered blood is collected in a collection unit.
- the blood cell concentration gradient is formed by standing for 5 minutes or more and less than 300 minutes
- the blood cell concentration gradient is formed by controlling the flow of liquid for a predetermined time, (1) or
- the hematocrit value of the blood in the lower part of the reservoir is not less than 1.05 times and less than 2.50 times the hematocrit value when the whole blood product in the reservoir is homogeneously mixed.
- a storage unit for storing blood a holding unit for holding the storage unit, a leukocyte removal filter, a collection unit for collecting blood filtered by the filter, a storage unit and a leukocyte removal filter 1st connecting pipe to connect, white blood
- a blood filtration device including a sphere removal filter and a second connection pipe connecting the collection section; a flow control means provided in the first connection pipe and / or the second connection pipe for controlling the flow of blood;
- a blood filtration device comprising: a signal generation means interlocked with the flow control means; and an operation means for automatically canceling the flow control means based on a signal from the signal generation means.
- Blood cells contained in blood have different specific gravity, red blood cells are about 1.08, granulocytes and monocytes are It is known that about 1.07, lymphocytes are about 1.06, and platelets are about 1.03, almost the same as plasma. If blood containing blood cells having different specific gravities is left as it is, a concentration gradient of blood cells is formed due to the specific gravity difference.
- the blood filtration method of the present invention is a method utilizing such properties.
- first blood filtration method of the present invention a blood cell concentration gradient is formed in advance in a blood storage portion to obtain a blood in an inhomogeneous state, and the blood is introduced into a leukocyte removal filter from the blood at the lower portion of the storage portion.
- this blood filtration method is referred to as “first filtration method”. More specifically, the “first filtration method” of the present invention is a method suitable for filtering a whole blood product, and is a method for storing a whole blood product, which is a storage section represented by a blood bag.
- the “first filtration method” of the present invention is a method of filtering substantially all of the blood contained in the reservoir with one filter.
- the blood is mixed so that the blood has a homogeneous blood cell concentration before being filtered through a leukocyte removal filter.
- the reason for the homogeneous mixing is to prevent the effective filtration area of the filter from being blocked at the initial stage of filtration by microaggregates contained in blood. Since microaggregates are larger and heavier than blood cells, they will sediment at the bottom of the reservoir in heterogeneous conditions. When filtration is started in such a state, the sedimented microaggregates come into contact with the filter relatively quickly, and at the initial stage of filtration, clogging occurs in the effective filtration portion of the filter, which greatly increases the filtration time due to one-sided flow, However, there is a risk that the filter performance will be significantly reduced.
- the present inventors have conducted intensive studies on relatively fresh whole blood products stored at room temperature, and found that after forming a blood cell concentration gradient to make the blood cells heterogeneous, blood having a high concentration of red blood cells and granulocytes was obtained. It was found that, even when filtration was performed, the above-mentioned inconveniences were not observed, and surprisingly the leukocyte removal ability was significantly improved.
- the platelet collection rate is unexpectedly improved. Even if a blood cell concentration gradient is formed in the present invention, the reason why liquid permeability was unexpectedly ensured is that fresh whole blood products that have a short storage period after blood collection have a low content of microaggregates, as described above. It is conceivable that such a problem derived from the micro aggregates did not occur. Also, compared to the concentrated erythrocyte product, the whole blood product has more plasma, so it is unlikely that a portion with a significantly increased viscosity is formed, so that sufficient liquid permeability could be secured. However, significant improvements in leukocyte removal and platelet recovery were unexpected.
- the present inventors fill a filter having a platelet collection function with blood, and thereafter perform a liquid passing control for holding or stopping the liquid passing at a low speed for a predetermined time, and thereafter, perform the blood passing control. It was surprisingly found that the second hemofiltration method, which filters the liquid, significantly improved the platelet recovery rate (hereinafter, this method is referred to as “second filtration method”).
- the “second filtration method” of the present invention is a method suitable for removing white blood cells contained in a whole blood product or a platelet product such as a platelet-rich product or a platelet-rich plasma and allowing the platelets to pass therethrough.
- a control is performed to maintain or stop the flow of blood at a low speed for a predetermined time, and during this control, the blood cell concentration in the blood in the reservoir is controlled.
- This method forms a gradient, then releases the flow control means, starts filtration, and collects blood from which leukocytes have been removed by a filter in a collection unit such as a blood bag.
- the "second filtration method” like the "first filtration method", is a method in which substantially all blood contained in the reservoir is filtered by one filter.
- the “second filtration method” significantly improved the platelet collection rate.
- One is that the blood in the reservoir forms a blood cell concentration gradient by the flow control for a predetermined time after the filter is filled with blood, and the same effect as the “first filtration method” caused by the concentration gradient formation is obtained. That is obtained.
- the other is that the filter material was moistened with blood during the flow control, and the surface was evenly covered with plasma proteins such as albumin, making it difficult for platelets to adhere.
- Filling the filter with blood in the second filtration method of the present invention refers to an operation from the introduction of blood into the filter through the filter inlet until the blood is extracted from the outlet. In this operation, if the entire filter material is moistened with blood, the platelet recovery rate is further improved. Therefore, it is preferable to fill the filter with blood so that air does not remain in the filter as much as possible.
- the flow control according to the present invention refers to maintaining or stopping blood flow at a low speed.
- “keeping blood flow at a low speed” means a state in which almost no blood flows.
- the average linear velocity of blood exceeds O cm minutes and is 0.2 cmZ or less.
- the average linear velocity is more than 0 cm and not more than 0.1 cm
- “stopping blood flow” is a state in which blood does not flow at all, that is, an average of 0 c minutes.
- the above-mentioned “average linear velocity” refers to the blood flow velocity (m LZ) divided by the effective filtration area (cm 2 ) of a filter through which blood can flow, perpendicular to the direction of blood flow.
- a plurality of filter materials with different effective filtration cross-sections may be included.
- the average value of the effective filtration cross-sections of one material of each filter is used.
- the flow is maintained or stopped at a low speed.Either control may be performed. The force operation is simple, and the reason that the platelet recovery rate is further increased. It is preferable to stop the operation.
- the fluid flow control of the present invention has a function of maintaining or stopping blood flow at a low speed, for example, compresses clamps such as a roller clamp, a slide clamp, a Robert clamp, and a connecting pipe such as a forceps. It can be implemented with a deformable jig or a pump that can control the linear velocity of blood.
- a deformable jig or a pump that can control the linear velocity of blood.
- the “first filtration method” and the “second filtration method” of the present invention are suitable methods particularly when a whole blood product is to be filtered.
- the whole blood product mentioned here is a product that has been subjected to artificial processing, such as adding an appropriate amount of anticoagulant to the collected whole blood, but the volume of the whole blood product to be filtered is There is no particular limitation. More specifically, it contains anticoagulants such as ACD (acid citrate dextrose) and CPD (citrate / phosphate / dextrose) within 3 days after blood collection, preferably within 1 day, more preferably Is blood within 8 hours.
- ACD acid citrate dextrose
- CPD citrate / phosphate / dextrose
- Whole blood products stored for more than 3 days after blood collection and / or whole blood products stored at or below 4 ° C have a high amount of microaggregates and may have small It is not preferable because the filter may be blocked by agglomerates and cause poor flow. It is not preferable to store at a temperature higher than 30 ° C because the denaturation of the plasma protein is likely to occur. It has a blood cell concentration gradient in the “first filtration method” and the “second filtration method” of the present invention.
- a whole blood product having a blood cell concentration gradient preferably has a hematocrit value of not less than 1.05 times and less than 2.50 times the hematocrit value when the hematocrit value in the lower part of the reservoir is homogeneously mixed. If the hematocrit value in the lower part of the reservoir is less than 1.05 that when homogeneously mixed, the formation of a blood cell concentration gradient is insufficient, and the leukocyte removal ability and the platelet recovery rate tend not to be improved. If it exceeds 2.50 times, the filtration time may be prolonged due to an increase in blood viscosity, hemolysis due to an increase in pressure loss, or a significant decrease in fluid permeability may be induced.
- the more preferable hematocrit value at the lower part of the storage part is 1.05 times or more and less than 2.0 times the hematocrit value when mixed homogeneously, and more preferably 1.20 times or more and 1.70 times. Desirably less than twice.
- the hematocrit value in the lower part of the reservoir of a whole blood product having a blood cell concentration gradient is 35% or more and less than 75%. If it is less than 35%, the formation of a blood cell concentration gradient may be insufficient, and the leukocyte removal ability and platelet recovery may not be improved. If it is more than 75%, filtration time may be prolonged or pressure loss may be reduced. The increase may cause hemolysis or a significant decrease in fluid permeability. More preferably, it is 45% or more and less than 65%.
- the hematocrit value in the lower part of the reservoir is preferably measured by directly sampling 2 to 3 mL of blood from the lower part of the reservoir, but if sampling is difficult, use a whole blood product.
- the hematocrit value can be measured by a known method such as a centrifugation method such as a microhematocrit method, a conductivity measurement method, a pulse height method, a measurement method using an automatic blood cell counter, and the like.
- a whole blood product having a blood cell concentration gradient has a blood cell separation degree of 3% or more and less than 60%, and more preferably 10% or more and less than 45%. It is desirable that
- the degree of blood cell separation is the ratio of the volume of the phase, which is substantially free of red blood cells and mainly composed of lymphocytes having a low specific gravity to plasma and platelets, to the total blood volume. If the blood cell separation is less than 3%, the formation of a blood cell concentration gradient is insufficient and no improvement in filter performance is observed.If it is 60% or more, the hematocrit of the blood at the lower part of the reservoir becomes too high.
- a method for preparing a whole blood product having a blood cell concentration gradient includes a so-called static method, in which blood stored in a reservoir is allowed to stand, and a whole blood product.
- a centrifugal method for centrifuging the collected storage section can be used.
- the stationary time is preferably 5 minutes or more and less than 300 minutes. If the time is less than 5 minutes, a sufficient concentration gradient formation of blood cells may not be formed, and if the time is more than 300 minutes, the standing time becomes too long, and it becomes difficult to filter a large amount of blood. Therefore, it is not preferable. More preferably, it is 10 minutes or more and less than 180 minutes, and more preferably 30 minutes or more and less than 120 minutes.
- a blood cell concentration gradient is formed by centrifugation
- light centrifugation is preferred.
- approximately 100 to 120 X g, preferably 100 to 500 X g It is desirable to centrifuge for 0.3 to 10 minutes with centrifugal force. If the centrifugation is weaker than this, it is not preferable because the formation of a blood cell concentration gradient is insufficient. If the centrifugation is stronger, the hematocrit value of the portion settled in the reservoir becomes higher, and filtration is performed in this state. This is not preferable because it increases the filtration time due to an increase in blood viscosity and increases the pressure loss when filtering at a constant flow rate, which may cause hemolysis of red blood cells.
- the whole blood product having a blood cell concentration gradient can be adjusted by any of the above-mentioned stationary method and centrifugation method, but is left stationary from the viewpoint of easy operation. More preferably, it is a method.
- the platelets are activated slightly by centrifugal stress in the centrifugation method. There is a tendency. For this reason, it is desirable to provide a stationary time of a predetermined time after the formation of the blood cell concentration gradient by the centrifugal method in order to calm the activated platelets.
- the standing time for platelet sedimentation is preferably 5 minutes or more and less than 180 minutes, and more preferably 10 minutes or more and less than 90 minutes.
- the flow control time at this time is preferably 5 minutes or more and less than 300 minutes. If the control time is less than 5 minutes, the platelet collection rate may not be improved due to insufficient formation of the blood cell concentration gradient in the reservoir or difficulty in covering the filter material with plasma protein. Not so suitable. If the time is longer than 300 minutes, the time for controlling the passage of the fluid becomes too long, and it becomes difficult to filter a large amount of blood, which is not preferable. More preferably from 10 minutes to less than 180 minutes, most preferably from 30 minutes to less than 120 minutes.
- the “second filtration method” of the present invention is an effective method not only for filtering whole blood but also for filtering platelet concentrates and platelet-rich platelet-rich plasma products.
- Platelet products such as concentrated platelet products and platelet-rich plasma are platelet products prepared by centrifuging collected whole blood products or platelet products prepared by component blood collection, and within 5 days after preparation It is preferred that Further, after such a platelet preparation is prepared, it is preferably a platelet preparation that has been shaken and stored at a room temperature of 20 ° C. or more and less than 25 ° C. until filtration through a filter. Platelet preparations stored more than 5 days after the adjustment and outside the above temperature range are not preferred because they may cause a decrease in platelet function and the like.
- a platelet product having a blood cell concentration gradient refers to a product in which the leukocyte concentration in the lower part of the reservoir is 1.05 times or more that when uniformly mixed. When the ratio is less than 1.05, the leukocyte removal performance tends to decrease, which is not preferable. More preferably, it is at least 1.20 times and less than 2.50 times.
- the leukocyte concentration in the lower part of the reservoir can be measured by sampling 2 to 3 mL from the lower part of the reservoir or sampling the first 2 to 3 mL introduced into the connecting pipe connected to the reservoir.
- the nucleus can be stained and measured using a microscope.
- the blood filtration method of the present invention may be carried out using a storage part for storing blood, a collection part for collecting filtered blood, and a hollow tubular connecting tube connecting the collection part with the filter. preferable.
- connection by connecting pipe is aseptic connection device (SCD) May be used.
- the connecting pipe is not particularly limited as long as it does not damage blood cells. Among them, organic materials such as vinyl chloride, silicon, polysulfone, polyamide, polyester, urethane, polyethylene, and polypropylene are preferable because of their excellent workability.
- the storage unit for storing blood is a container that can store blood, and any container can be used without particular limitation as long as it does not cause activation of blood cells or significant adsorption or denaturation of plasma proteins. More specifically, there may be mentioned blood bags made of soft polychlorinated vinyl and polyolefin widely used for blood collection and preservation, and syringes made of polypropylene, polyethylene and polystyrene.
- the collecting part for collecting blood is a container capable of collecting and storing blood, and any container can be used without particular limitation as long as it does not cause activation of blood cells or significant adsorption or denaturation of plasma proteins.
- the collecting unit may include at least one or more containers for collecting the blood after filtration and then collecting each component by centrifugation. More specifically, a blood bag made of flexible polychlorinated biel and polyolefin, which are widely and generally used for collecting and storing blood, can be mentioned.
- a leukocyte removal filter that can be suitably used in the present invention is a filter that has a blood inlet and outlet and is filled with a filter material that can capture and remove leukocytes mixed into blood, and is a known leukocyte removal filter. Any of the filters can be used. More specifically, the logarithmic value (one log (white blood cell concentration after filtration and white blood cell concentration before filtration)) of the value obtained by dividing the residual leukocyte concentration after filtration by the leukocyte concentration before filtration is defined as the leukocyte removal ability. It means a filter whose value becomes 2.30 or more, preferably 3.00 or more.
- the filter material examples include a fibrous medium and a sponge-like medium. If the filter material does not adversely affect the blood, the surface of the filter material is modified by coating with a hydrophilic polymer or by radiation graft polymerization for the purpose of making the filter material easily wet with blood. May be.
- a platelet low-adhesive material may be introduced to the surface of the filter material.
- a platelet low-adhesive material Japanese Patent Publication No. 6-51060—as described in JP-A-1-249906, etc.
- Suitable materials include a polymer having a hydrophilic group and a chargeable group such as an amino group or a carboxyl group, or polyurethane. It can be mentioned as.
- the blood filtration method of the present invention is a method of filtering blood with a leukocyte removal filter.
- the blood may be filtered after securing an appropriate head using a blood bag or the like as a reservoir, or a fixed flow rate using a pump or the like. May be used for filtration.
- a second object of the present invention is to provide a stationary or fluid control for a predetermined time before actually starting blood filtration with a filter, such as the “first filtration method” and the “second filtration method”. To provide a device that can automatically perform the necessary blood filtration method.
- An object of the present invention is to provide a blood filtration device for performing the “first filtration method” and the “second filtration method” while reducing the burden on a filtration practitioner and performing stable filtration performance of the filter.
- the blood filtration device of the present invention will be described in detail with reference to the accompanying drawings.
- the blood filtration device of the present invention is not limited to only the specific examples in the accompanying drawings.
- the blood filtration device (1) of the present invention includes a blood storage section (2) represented by a blood bag and a blood storage section (2) represented by a hook.
- the holding part (11), the collecting part (3), and the filter (4) having a blood inlet and a blood outlet are connected by a hollow tubular connecting pipe (5, 6).
- the flow control means (7, 7 ') is a device that is automatically released by the operating means (10) based on the signal from the signal generating means (8, 9).
- the flow control means (1) in the first connection pipe (5) and / or the second connection pipe (6) before the blood is actually filtered by the filter (4), the flow control means (1) in the first connection pipe (5) and / or the second connection pipe (6). According to 7, 7 '), the flow is maintained at a low speed or stopped, and the blood is not substantially passed for a predetermined time.
- the actuating means (10) recognizes the signal emitted from the signal generating means (8, 9) to be described later, and then the signal from the actuating means (10) is sent to the flow control means (7, 7 '). As a result, the blood flow control is automatically released, and the filtration is started.
- the blood filtration device (1) of the present invention comprises: a flow control means (7, 7 '); a signal generation means (8, 9); (10) must be linked.
- “linked” means that the signal from the signal generation means (8, 9) can be automatically transmitted to the liquid flow control means (7, 7 ') through the operation means (10). It means that the flow control means (7, 7 '), the signal generating means (8, 9) and the operating means (10) are electrically connected.
- the actuating means (10) may be a device integrated with the signal generating means (8, 9) and Z or the flow control means (7, 7 '), or may be a device independent of itself. Is also good.
- the signal generating means is a device having a function of transmitting a signal to the operating means (10) after a predetermined time or after the blood reaches a state where a predetermined blood cell concentration gradient is formed.
- An example of the signal generation means (8) in FIG. 1 is a timer for releasing the liquid flow control means (7, 7 ′) after a predetermined time, and the signal generation means (9) in FIG.
- a preferred example is an optical sensor capable of detecting the state of formation of the blood cell concentration gradient (ie, the degree of blood cell separation) in the section (2) and interlocking with the flow control means (7, 7 ').
- the timer can be used for both the “first filtration method” and the “second filtration method”.
- the timer when the timer is used as the signal generating means (8), the blood is collected after the storage section (2) is held by the holding section (1 1) and left standing, or after the filter (4) is filled with blood.
- the timer After controlling the flow, the timer is set to emit a signal when a predetermined time has elapsed. This signal is transmitted to the flow control means (7, 7 ') via the operating means (10), The flow control means (7, 7 ') is automatically released and filtration starts.
- the optical sensor is a signal generating means that can be particularly preferably used when performing filtration on whole blood products among blood.
- the storage section (2) When filtering a whole blood product using an optical sensor as the signal generating means (9) with a blood filtration device as shown in Fig. 2, the storage section (2) must be held by the holding section (1 1) and allowed to stand still. Thus, a blood cell concentration gradient is formed, and when the optical sensor detects that the blood cell separation degree has been reached, a signal is issued from the sensor. This signal is passed through the operating means (10) and the flow control means (7, 7 ') and the automatic release of the flow control is performed.
- a sensor that optically detects the location of the liquid interface (for example, the interface between a phase rich in plasma, platelets and light lymphocytes and a phase rich in red blood cells, heavy granulocytes and monocytes) Can be mentioned.
- This sensor has a light emitting element and a light receiving element, and the light emitted from the light emitting element is reflected by blood and receives the reflected light. As the blood cell separation progresses and the blood interface reaches the position where the sensor is installed, the intensity of the reflected light changes.
- a sensor is installed at a position that provides an appropriate degree of blood cell separation, and when the intensity of the reflected light changes, a signal is sent from the sensor and the flow control means (7, 7 ') is used. By automatically canceling, blood filtration starts.
- FIG. 5 there is a form in which a sensor having a light emitting element and a sensor having a light receiving element are attached to both sides so as to sandwich the blood reservoir (2).
- This sensor detects the intensity of transmitted light.
- the blood interface reaches the position of the sensor, that is, when the transmitted light intensity increases, a signal is issued from the sensor, and the liquid release means (7, 7 ') will be canceled automatically.
- sensors attached to the upper and lower parts of the blood storage unit emit a signal when the difference between the intensity of the reflected light or transmitted light between the upper part and the lower part reaches a certain value.
- a sensor that automatically releases the liquid releasing means (7, 7 ') can also be used in the present invention.
- the blood flow control means (7, 7 ') in the blood filtration device of the present invention has a function of maintaining or stopping blood flow at a low speed, and generates a signal from the above-described timer or optical sensor.
- means (8, 9) cooperates with the signal generating means (8, 9) Yotsute on whether these signals. automatically particularly limited as long as it can be released passed through control by a les.
- a clamp, a valve, a pump and the like can be exemplified.
- the release of the liquid flow control means (7, 7 ') means, for example, in the case of controlling the liquid flow by compressing the connection pipe with a clamp or a valve, the compression is released, and the connection pipe is released so that blood flows. It means to increase the opening diameter.
- a soft blood bag is used as the blood reservoir (2), the bag may be deformed and the detection of the interface by the optical sensor may become unstable.
- a holder for keeping the shape of the blood bag constant may be provided.
- the holding part (1 1) for holding the blood storing part (2) of the present invention is not particularly limited as long as it has a function of holding the storing part at a predetermined position, and any type can be used. It is particularly preferable that the device be able to stand still without giving vibration. More specifically, a hook or the like that can hook the storage portion and hang it to a desired head can be given.
- the liquid flow control means (7, 7 ') is automatically released by a signal generation means (8, 9) such as a timer or an optical sensor, so that 0.5 ⁇ !
- the blood may be filtered at an appropriate head of about 2 m or by a pump linked to the signal generating means (8, 9), and the form of filtration is not particularly limited.
- the whole blood product is filtered by the blood filtration method and / or the hemofiltration device of the present invention, after obtaining a whole blood product from which leukocytes have been removed, the blood component product from which leukocytes have been removed by a known centrifugation method. It can also be adjusted.
- the HM-3 polymer has a monomer concentration of 1 mol ZL in ethanol and uses 2,2'-azobis (2,4-dimethylvaleronitrile) (Wako Pure Chemical Industries, V-65) as an initiator. It was synthesized by random polymerization at 60 ° C. for 8 hours in the presence of 1 Z200 mol ZL.
- the following operation was performed when coating the synthesized HM-3 polymer on the surface of the nonwoven fabric.
- the nonwoven fabric is punched to a diameter of 25 mm, immersed in this polymer solution at 25 ° C for 1 minute, filled in a polycarbonate holder, aerated with dry nitrogen for 4.5 minutes, and then vacuum dried at 60 ° C for 18 hours. By coating.
- a filter for filtering blood is made by punching a non-woven cloth to a diameter of 2 Omm, filling an effective filtration cross-sectional area of 1.33 cm 2 , and conducting blood; It was produced by doing so.
- a non-woven fabric coated with HM-3 was used, the dried non-woven fabric coated with HM-3 was taken out of a polycarbonate holder, punched to a diameter of 2 Omm, and then filled into 16 sheets.
- the leukocyte concentration in the whole blood product before filtration was measured using a blood sampled from a homogenous whole blood product, staining the leukocyte with Turk's solution, and using an optical microscope.
- the leukocyte concentration in the whole blood product after filtration was measured by using a fluorescence microscope after sampling the collected blood in a polyethylene Spitz tube, staining the leaked leukocytes with acridine orange solution, and then using a fluorescence microscope. From the leukocyte concentrations before and after filtration thus obtained, the leukocyte removal ability was determined by the following equation.
- Leukocyte removal ability 1 L o g (white blood cell concentration after filtration, white blood cell concentration before filtration)
- Platelet recovery Platelet concentration after filtration Z Platelet concentration before filtration X 100 (%)
- the hematocrit value in a homogeneous state (hereinafter, referred to as pre-Ht) and the hematocrit value in the lower part of the syringe (hereinafter, referred to as post-Ht) were measured by the following methods.
- the pre-Ht value was measured by thoroughly mixing the unfiltered whole blood product remaining in the blood bag and sampling 2 mL of blood therefrom.
- Bost Ht of a whole blood product with a blood cell concentration gradient another syringe containing a whole blood product was prepared, and after leaving it for a certain period of time, 2 mL of blood at the lower part of the syringe was collected. It was used for Ht measurement.
- the mixture was mixed again, and 2 mL of blood at the lower part of the syringe was collected and used for post-Ht measurement.
- the pre- and post-Ht measurements were performed by placing the sampled blood in a polyethylene pipette and using a multi-item automatic hemocytometer in the same manner as the measurement of the platelet concentration.
- pre-Ht 34%
- post-Ht 52%
- leukocyte removal ability was 3.72
- platelet collection rate was Was 84%.
- HEMA and DE random copolymer
- the molar composition ratio was 95: 5; hereinafter, abbreviated as HE-5).
- the synthesis of HE-5 polymer, coating on a nonwoven fabric, and filtration of blood were performed under the same conditions and method as in Example 1. As a result, the leukocyte removal ability was 3.65, and the platelet recovery was 85%.
- a random copolymer consisting of hydroxypropyl methacrylate (HPMA) and DM (the molar composition ratio of HPMA and DM is 97: 3; hereinafter abbreviated as PM-3) is used as a low platelet adhesive material.
- a random copolymer consisting of HPMA, DM and methoxydiethylene glycol methacrylate (DEG) (the molar composition ratio of HPMA, DM and DEG is 90: 3: 7; hereinafter abbreviated as PMD) is used as a low platelet adhesive material.
- PMD methoxydiethylene glycol methacrylate
- the platelet low-adhesion polymer-coated leukocyte removal filter formed not only the leukocyte removal ability but also the platelet collection rate by forming a blood cell concentration gradient. It can be seen that it has been significantly improved.
- a filter which was not coated with the platelet low-adhesion polymer but filled with the same nonwoven fabric as in Example 1 was produced.
- a CPD-added whole blood product 3 hours after blood collection was collected in a syringe, allowed to stand for 60 minutes, and then filtered in the same manner as in Example 1.
- the pre-Ht was 39%
- the post-Ht was 62%
- the leukocyte removal ability was 4.34.
- Example 8 Comparing the results of Example 8 with Comparative Example 2, it was found that in the leukocyte removal filter not coated with the platelet low-adhesion polymer, the leukocyte removal ability was significantly improved by forming a blood cell concentration gradient.
- this nonwoven fabric is abbreviated as a prefilter.
- a non-woven fabric with an average fiber diameter of 1.7 nm and a basis weight of 66 g / m and a thickness of 0.4 mm (hereinafter, this non-woven fabric is abbreviated as main filter A), and the same non-woven fabric as in Example 1 (hereinafter, This nonwoven fabric is abbreviated as main filter 1B.) was coated with HM-3 polymer. However, coating was performed by the following operation.
- each nonwoven fabric is cut into a size of 10 cm, and immersed in a polymer solution in which HM-3 is dissolved at 25 ° C for 1 minute. After that, the nonwoven fabric wetted with the HM-3 liquid was compressed to about half the thickness to remove excess liquid, dried at room temperature for 24 hours, and coated. This operation was performed one by one until the required amount of non-woven fabric was obtained after coating the filter.
- the prefilter 1 was coated with a solution having a HM-3 concentration of 5 gZd L, and the main filters A and B were coated with a solution having a HM-3 concentration of 7 g / / L.
- the coated non-woven fabric thus obtained was placed in a polycarbonate container having an effective filtration area of 45 cm 2 , and two pre-filters were passed from the blood inlet side to the outlet side. Filters were prepared by filling two main filters A and 28 main filters B and then ultrasonically welding.
- the inlet of the above filter was inserted into a CPD-added whole blood product (450 mL) that was collected in a flexible polyvinyl chloride blood bag and stored at room temperature (22 to 24 ° C) for 3 hours.
- the connection was made via a tube fitted with a 9 mm clamp, and the filter outlet and the collection bag were connected with the same tube.
- the blood bag containing the whole blood product was hooked on a hook, and the head was set at 1. Om. After standing for 60 minutes, the clamp was released, and the blood filtered through the filter was collected in a collection bag.
- the hematocrit value was measured from the blood sampled from a homogeneous state and the blood sampled from the lower part of the blood bag after standing for 60 minutes in the same manner as above.
- Example 11 Filtration was performed under the same conditions and method using the same nonwoven fabric, coating and filter as in Example 9 except that the same low platelet adhesion polymer as in Example 7 was used.
- the leukocyte removal ability was 4.30 and the platelet collection rate was 92%.
- a blood bag made of soft polyvinyl chloride containing fresh whole blood with CPD stored at room temperature for 3 hours after blood collection is placed in a centrifuge (Model CR7B3, manufactured by Hitachi, Ltd.) and centrifuged at 300 X g. And centrifuged briefly for 0.5 minutes to prepare a whole blood product (28 mL) having a blood cell density gradient.
- a filter was prepared in which 16 non-woven fabrics coated with HM-3 similar to those in Example 1 were filled in a holder having an inner diameter of 25 mm and stacked.
- a polyvinyl chloride tube with an inner diameter of 2.5 mm was connected to a blood bag containing a whole blood product in which a blood cell concentration gradient was formed by centrifugation, and the blood inlet of the filter was connected to the other end of the tube.
- a blood outlet and a blood bag for collecting the filtered whole blood product were connected via the same tube.
- Pre-Ht is measured by sampling blood from a homogenous whole blood product before centrifugation
- post-Ht is measured by allowing the blood bag containing the centrifuged whole blood product to stand for 5 minutes. It was measured by sampling from the lower part of the bag.
- a blood bag containing a whole blood product having a blood cell density gradient after connection of the filter was suspended, and filtration was performed at a head of 40 cm.
- the leukocyte removal ability was 3.48 and the platelet collection rate was 76. /. Met.
- Example 2 The following second filtration method was performed using the same nonwoven fabric, platelet low-adhesion polymer, and filter as in Example 1. The measurement of leukocyte removal ability and platelet collection rate was the same as in Example 1. Performed in a similar manner.
- Blood was collected in a flexible polychlorinated blood bag and stored at room temperature (20 to 25 ° C) for 2 to 3 hours. After thoroughly mixing the CPD-added whole blood product, 8 mL of the blood was syringed with the syringe ( Collected by Terumo Syringe ( Rs S-20 ESZ) manufactured by Terumo. A syringe made of a whole blood product was connected to a tube made of polychlorinated vinyl having an inner diameter of 2.5 mm, and the other end of the tube was connected to the blood inlet of the above-mentioned filter.
- syringe Collected by Terumo Syringe ( Rs S-20 ESZ) manufactured by Terumo.
- a syringe made of a whole blood product was connected to a tube made of polychlorinated vinyl having an inner diameter of 2.5 mm, and the other end of the tube was connected to the blood inlet of the above-mentioned filter.
- the same tube equipped with a clamp was connected to the blood outlet of the filter, and a bag made of soft polyvinyl chloride was arranged as a collection bag to collect blood drawn from the opposite end.
- the syringe containing the whole blood product was mixed well and filled into the filter using a pump at a constant average linear velocity of 0.68 cmZ (flow rate of 0.9 mL / min).
- the pump was stopped, the tube was closed using a clamp between the filter and the collection bag, and the flow of blood was stopped for 60 minutes. Thereafter, the clamp was released, the pump was restarted, and filtration was performed at a constant average linear velocity of 0.68 c.
- the leukocyte removal ability was 3.58, and the platelet collection rate was 92%.
- Filtration was performed by the same method as in Example 13 except that the filtration was performed without a stop time after filling the filter with blood, and the same method was used. As a result, the leukocyte removal ability was 3.64, and the platelet collection rate was 64%.
- Comparative Example 4> The same filter as in Example 13 was used except that the filter was filled with physiological saline instead of blood, and filtration was performed in the same manner. As a result, the leukocyte removal ability is 3.
- Example 13 Using the same nonwoven fabric, polymer, and filter as in Example 5, filtration was performed under the same conditions and method as in Example 13. As a result, the leukocyte removal ability was 3.48 and the platelet recovery was 93%.
- Blood is collected in a flexible polychlorinated bull blood bag and stored at room temperature (22 to 24 ° C) for 4 hours. Mix well with 450 mL of CPD-added whole blood, and filter blood in a tube equipped with a clamp. Connected to the inlet. In addition, the blood outlet of the filter and the collection bag were connected with the same tube, and the bag containing the whole blood product was placed at a height of 1. Om. When the filter was filled with the homogenous whole blood product, the clamp was closed and the flow was stopped for 60 minutes. Thereafter, the clamp was released and filtration was performed. As a result, the leukocyte removal ability was 3.64, and the platelet recovery rate was 95%.
- the filter was filled with the whole blood product at a constant average linear velocity of 0.68 c. Then, change the pump setting to maintain the average linear velocity of 0.08 cmZ for 5 minutes, then change the pump setting again to 0.
- the filtration was returned to an average linear velocity of 68 cm / min.
- the leukocyte removal ability was 3.61
- the platelet collection rate was 78%.
- HM-3 nonwoven fabric 1 four coated is in effective filtration sectional area is 1. 33 cm 2, filled into a container having inlet and outlet of the blood Created a filter by doing Centrifuge the whole blood product supplemented with CPD, collect 8 mL from the concentrated platelet product stored with shaking at 22-24 ° C for 3 days, mix well, and filter by the same method as in Example 13. Was done. However, The platelet concentrate is filled into the filter using a pump at a constant linear velocity of 0.92 cmZ (flow rate of 1.2 mLZ) .After filling, the flow of the platelet concentrate is stopped for 30 minutes. Filtration was performed at a constant linear speed of 92 cmZ.
- Leukocyte removal ability and platelet recovery were performed in the same manner as in Example 1. As a result, the leukocyte removal ability was 3.20 and the platelet collection rate was 88%.
- an operation method and preferable conditions when blood is filtered using the blood filtration device of the present invention will be described.
- the flow control means (7, 7 ') When performing the “-th filtration method” using a timer as a signal generation means (8) with a blood filtration device as shown in Fig. 1, first, the flow control means (7, 7 ') is closed, and the blood is filtered. Hang the blood reservoir (2) filled with. After setting the blood reservoir (2) on the hook, set the timer. When the time set in the timer elapses, the flow control means (7, 7 ') is released by the operating means (10) based on the signal from the timer, and the blood automatically starts flowing. Then, the blood from which leukocytes have been removed through the leukocyte removal filter (4) is collected in the blood collection section (3).
- the time required for the liquid flow control means (7, 7 ') to be automatically released by the timer is preferably 5 minutes or more and less than 300 minutes, preferably 10 minutes or more and less than 180 minutes after the blood reservoir (2) is hooked. It is desirable that the time is 30 minutes or more and less than 120 minutes. If the time is less than 5 minutes, it may be difficult to form a sufficient blood cell concentration gradient, and if the time is more than 300 minutes, it becomes difficult to filter a large amount of blood, which is not preferable.
- a blood reservoir (2) filled with blood is hooked on a hook.
- the leukocyte removal filter (4) is filled with blood, close the flow control means (7, 7,) and set the timer.
- the operating means (10) releases the flow control means (7, 7 ') based on the signal from the timer, and the blood flows automatically.
- the blood from which leukocytes have been removed through the leukocyte removal filter (4) is collected in the blood collection section (3).
- the time for controlling the flow after filling the filter with blood is preferably from 5 minutes to less than 300 minutes, preferably from 10 minutes to less than 180 minutes, and more preferably from 30 minutes to less than 120 minutes. . If the flow control time is less than 5 minutes, the effect of filling the filter with blood is not obtained, and the platelet recovery rate may not be improved. If it is longer than 300 minutes, it becomes difficult to filter a large amount of blood, which is preferable.
- the blood reservoir (2) When performing the “first filtration method” using an optical sensor as the signal generating means (9) in a blood filtration device as shown in FIG. 2, the blood reservoir (2) is filled with blood, and the flow control means ( 7, 7 ') is closed, and the blood reservoir (2) is hooked.
- the operating means (10) automatically releases the flow control means (7, 7 ') based on the signal from the sensor, and the blood is removed.
- the blood flow is started, the leukocyte is removed through the leukocyte removal filter (4), and the blood is collected in the blood collection part (3).
- the value of blood cell separation is preferably 3% or more and less than 60%, more preferably 10% or more and less than 45%. If the blood cell separation is less than 5%, the formation of a blood cell concentration gradient is insufficient and no improvement in the filter performance is observed. This may cause hemolysis due to increased pressure loss or pressure loss.
- the blood filtration method of the present invention leukocytes can be efficiently removed from a whole blood product. Furthermore, a high platelet recovery rate can be stably obtained while efficiently removing leukocytes from whole blood products and platelet products. That is, the blood filtration method of the present invention The method can be used as an effective method in transfusion medicine because it highly removes white blood cells that cause transfusion side effects or can recover platelets as a useful component at a high rate.
- the blood filtration device of the present invention is a particularly suitable device for performing the blood filtration method of the present invention.
- the burden on the filter executor can be reduced, and the filter performance can be increased and stabilized.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/475,987 US7217365B2 (en) | 2001-04-26 | 2002-04-26 | Blood filtration methods |
AT02722812T ATE530212T1 (de) | 2001-04-26 | 2002-04-26 | Blutfiltrationsmethode |
EP02722812A EP1382357B1 (en) | 2001-04-26 | 2002-04-26 | Blood filtration method |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-129176 | 2001-04-26 | ||
JP2001129177A JP2002320669A (ja) | 2001-04-26 | 2001-04-26 | 血液ろ過方法 |
JP2001-129177 | 2001-04-26 | ||
JP2001129176A JP2002322070A (ja) | 2001-04-26 | 2001-04-26 | 血液ろ過方法 |
JP2001262539A JP2003070903A (ja) | 2001-08-31 | 2001-08-31 | 血液ろ過装置 |
JP2001-262539 | 2001-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002087660A1 true WO2002087660A1 (fr) | 2002-11-07 |
Family
ID=27346617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004201 WO2002087660A1 (fr) | 2001-04-26 | 2002-04-26 | Procedes et dispositif de filtration du sang |
Country Status (4)
Country | Link |
---|---|
US (1) | US7217365B2 (ja) |
EP (1) | EP1382357B1 (ja) |
AT (1) | ATE530212T1 (ja) |
WO (1) | WO2002087660A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009284860A (ja) * | 2008-05-30 | 2009-12-10 | Asahi Kasei Kuraray Medical Co Ltd | 単核細胞と血小板の濃縮方法 |
WO2011115291A1 (ja) * | 2010-03-19 | 2011-09-22 | 旭化成メディカル株式会社 | 細胞除去方法、細胞除去システム及び白血球除去方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101098162B1 (ko) * | 2003-10-10 | 2011-12-22 | 아사히 카세이 쿠라레 메디칼 가부시키가이샤 | 세포 농축물의 조제 방법 및 세포 조성물 |
JP5422554B2 (ja) * | 2008-04-14 | 2014-02-19 | 旭化成メディカル株式会社 | 凝集物除去フィルター材及び血液製剤のろ過方法 |
EP3010522B1 (en) | 2013-05-21 | 2021-01-20 | President and Fellows of Harvard College | Engineered heme-binding compositions and uses thereof |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US11883570B2 (en) * | 2017-09-28 | 2024-01-30 | Terumo Kabushiki Kaisha | Blood transfusion kit and system and method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05322886A (ja) * | 1984-12-24 | 1993-12-07 | Kitos Inc | 血液試料の処理方法 |
JP2000334034A (ja) * | 1990-11-30 | 2000-12-05 | Terumo Corp | 血液成分分離方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424132A (en) * | 1981-02-05 | 1984-01-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Apparatus and method for separating blood components |
EP0349188B1 (en) * | 1988-06-23 | 1992-09-02 | ASAHI MEDICAL Co., Ltd. | Method for separating blood into blood components, and blood components separator unit |
US5100564A (en) * | 1990-11-06 | 1992-03-31 | Pall Corporation | Blood collection and processing system |
FR2677883B1 (fr) * | 1991-06-24 | 1997-07-18 | Maco Pharma Sa | Poche filtrante destinee a permettre la filtration sterile du sang et ensemble de poches de prelevement de sang. |
NL9320039A (nl) * | 1992-07-13 | 1995-04-03 | Pall Corp | Geautomatiseerd systeem en werkwijze voor het behandelen van biologisch fluidum. |
US5594164A (en) * | 1994-07-12 | 1997-01-14 | Bull; Brian S. | Method and apparatus for rapid determination of blood sedimentation rate |
ES2243023T3 (es) * | 1998-05-19 | 2005-11-16 | Terumo Kabushiki Kaisha | Metodo de eliminacion de globulos blancos. |
-
2002
- 2002-04-26 US US10/475,987 patent/US7217365B2/en not_active Expired - Fee Related
- 2002-04-26 EP EP02722812A patent/EP1382357B1/en not_active Expired - Lifetime
- 2002-04-26 WO PCT/JP2002/004201 patent/WO2002087660A1/ja active Application Filing
- 2002-04-26 AT AT02722812T patent/ATE530212T1/de not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05322886A (ja) * | 1984-12-24 | 1993-12-07 | Kitos Inc | 血液試料の処理方法 |
JP2000334034A (ja) * | 1990-11-30 | 2000-12-05 | Terumo Corp | 血液成分分離方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009284860A (ja) * | 2008-05-30 | 2009-12-10 | Asahi Kasei Kuraray Medical Co Ltd | 単核細胞と血小板の濃縮方法 |
WO2011115291A1 (ja) * | 2010-03-19 | 2011-09-22 | 旭化成メディカル株式会社 | 細胞除去方法、細胞除去システム及び白血球除去方法 |
JPWO2011115291A1 (ja) * | 2010-03-19 | 2013-07-04 | 旭化成メディカル株式会社 | 細胞除去方法、細胞除去システム及び白血球除去方法 |
JP5700576B2 (ja) * | 2010-03-19 | 2015-04-15 | 旭化成メディカル株式会社 | 細胞除去方法、細胞除去システム及び白血球除去方法 |
US9474845B2 (en) | 2010-03-19 | 2016-10-25 | Asahi Kasei Medical Co. Ltd. | Cell removal method, cell removal system, and white blood cell removal method |
US10117987B2 (en) | 2010-03-19 | 2018-11-06 | Asahi Kasei Medical Co., Ltd. | Cell removal method, cell removal system, and white blood cell removal method |
Also Published As
Publication number | Publication date |
---|---|
EP1382357B1 (en) | 2011-10-26 |
EP1382357A1 (en) | 2004-01-21 |
US20040200775A1 (en) | 2004-10-14 |
US7217365B2 (en) | 2007-05-15 |
EP1382357A4 (en) | 2008-07-30 |
ATE530212T1 (de) | 2011-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5217627A (en) | System and method for processing biological fluid | |
EP0556303B1 (en) | System and method for processing biological fluids | |
EP0349188B1 (en) | Method for separating blood into blood components, and blood components separator unit | |
US5543060A (en) | Method for processing blood for human transfusion | |
US7182865B2 (en) | Device for separating whole blood under gravitational force | |
EP1267990B1 (en) | Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species | |
EP1683857B1 (en) | Method of preparing cell concentrate and cell composition | |
SE514255C3 (sv) | System och metod för behandling av biologiska vätskor | |
JPS6085757A (ja) | 血漿搬出に有用な設備 | |
WO2002087660A1 (fr) | Procedes et dispositif de filtration du sang | |
US20060016753A1 (en) | Biological fluid filter | |
JP4107410B2 (ja) | 単球捕捉フィルター | |
JPH05317413A (ja) | 白血球除去血液成分採取装置 | |
JPH0624995A (ja) | 白血球捕捉材 | |
JP3208132B2 (ja) | 血液成分分離方法 | |
JP3088764B2 (ja) | 血液成分分離方法 | |
JP2003070903A (ja) | 血液ろ過装置 | |
JP2002320669A (ja) | 血液ろ過方法 | |
JP2001078757A (ja) | 細胞分離方法及び細胞分離用流体 | |
JP3157519B2 (ja) | 血液成分分離システム | |
JP2002322070A (ja) | 血液ろ過方法 | |
JPH0681729B2 (ja) | 血液洗浄装置 | |
CZ343991A3 (cs) | Způsob zpracování biologické tekutiny a zařízení k provádění tohoto způsobu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002722812 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002722812 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10475987 Country of ref document: US |